(Q43954392)

28 November 2017

title

Identifying improvement opportunities in the management of hepatitis C (English)

1 reference

28 November 2017

J F Márquez-Peiró

1

1 reference

28 November 2017

C Pérez-Peiró

series ordinal

2

1 reference

28 November 2017

J Carmena-Carmena

series ordinal

3

1 reference

28 November 2017

N V Jiménez-Torres

series ordinal

4

1 reference

28 November 2017

publication date

1 May 2006

1 reference

Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria

28 November 2017

published in

1 reference

28 November 2017

volume

30

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

154-160

1 reference

Hepatitis C: the clinical spectrum of disease

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Interferon alfa for chronic hepatitis C: how do we define cure?

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Treatment of hepatitis C. The 2002 French consensus

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

The management of chronic viral hepatitis: a Canadian consensus conference 2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

The management of side-effects during therapy for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Factors contributing to ribavirin-induced anemia

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Current therapy for hepatitis C: pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Use of growth factors with antiviral therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2806%2973966-6

7 January 2021

10.1016/S1130-6343(06)73966-6

Identifiers

DOI

1 reference

release_b73bsip45rbfnn72eloyglrb5a

28 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b73bsip45rbfnn72eloyglrb5a

24 November 2022

mapped directly with Wikidata item

1 reference